TrialSignal
Clinical trial intelligence report
A Phase IIa, Randomised, Parallel, Double-Blind,Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03645421-Jul 28, 2026
NCT ID
NCT03645421
Status
COMPLETED
Phase
Phase 2a
Sponsor
AstraZeneca
Executive brief
Investment-Ready Snapshot
MEDI0382, developed by AstraZeneca, targets the Japanese market for Type 2 Diabetes Mellitus (T2DM) treatment, particularly among preobese and obese patients with inadequate glycemic control. The competitive landscape includes established GLP-1 receptor agonists and emerging glucagon receptor agonists. The successful outcome of this trial could position AstraZeneca favorably against competitors, especially in a market where diabetes prevalence is rising. Diligence should focus on the safety profile and efficacy data, as these will be critical for regulatory approval and market acceptance.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03645421
Indication
Type 2 Diabetes
Modality
small molecule
Target
GLP-1 receptor and glucagon receptor agonists
Intervention
MEDI0382 100 μg, MEDI0382 200 μg, MEDI0382 300 μg, PlaceboA, MEDI0382 50 ug, PlaceboB
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.